Andrew S. Kraft

Andrew S. Kraft

Auto-generated profile, based on publicly available information

Andrew S. Kraft

Department of Medicine, Medical University of South Carolina, Charleston, SC 29425

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZXZuping Xia
Zuping Xia
CKChristian Knaak
Christian Knaak
JMJian Ma
Jian Ma
ZBZanna M. Beharry
Zanna M. Beharry
CMCampbell McInnes
Campbell McInnes
CSCharles D. Smith
Charles D. Smith

1 May 2009 in Cancer Biology & Therapy
Verified
Journal Article
Open access
FZFengxue Zhang
Fengxue Zhang
ZBZanna M. Beharry
Zanna M. Beharry
THThurl E. Harris
Thurl E. Harris
MLMichael B. Lilly
Michael B. Lilly
CSCharles D. Smith
Charles D. Smith
AKAndrew S. Kraft
Andrew S. Kraft
PIM1 is a serine /threonine kinase that has diverse biological roles in cell survival, proliferation and differentiation. PIM1 has been implicated in early transformation and tumor progression in...

28 January 2010 in Blood
Verified
Journal Article
Open access
PDF file
YLYing-Wei Lin
Ying-Wei Lin
ZBZanna M. Beharry
Zanna M. Beharry
EHElizabeth G. Hill
Elizabeth G. Hill
JSJin H Song
Jin H Song
WWWenxue Wang
Wenxue Wang
AKAndrew S. Kraft
Andrew S. Kraft
The serine/threonine Pim kinases are up-regulated in specific hematologic neoplasms, and play an important role in key signal transduction pathways, including those regulated by MYC, MYCN, FLT3-ITD, BCR-ABL, HOXA9, and EWS fusions. We demonstrate that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre–T-LBL/T-ALL) being highly sensitive. Incubation of pre–T-LBL cells with SMI-4a induced G1 phase cell-cycle arrest secondary to a dose-dependent induction of p27Kip1, apoptosis through the mitochondrial pathway, and inhibition of the mammalian target of rapamycin C1 (mTORC1) pathway based on decreases in phospho-p70 S6K and phospho-4E-BP1, 2 substrates of this enzyme. In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre–T-LBL cells. In immunodeficient mice carrying subcutaneous pre–T-LBL tumors, treatment twice daily with SMI-4a caused a significant delay in the tumor growth without any change in the weight, blood counts, or chemistries. Our data suggest that inhibition of the Pim protein kinases may be developed as a therapeutic strategy for the treatment of pre–T-LBL.

27 December 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ZBZanna Beharry
Zanna Beharry
SMSandeep Mahajan
Sandeep Mahajan
MZMarina Zemskova
Marina Zemskova
YLYing-Wei Lin
Ying-Wei Lin
BTBaby G. Tholanikunnel
Baby G. Tholanikunnel
AKAndrew S. Kraft
Andrew S. Kraft
The serine/threonine Pim kinases are overexpressed in solid cancers and hematologic malignancies and promote cell growth and survival. Here, we find that a novel Pim kinase inhibitor, SMI-4a, or Pim-1 siRNA blocked the rapamycin-sensitive mammalian target of rapamycin (mTORC1) activity by stimulating the phosphorylation and thus activating the mTORC1 negative regulator AMP-dependent protein kinase (AMPK). Mouse embryonic fibroblasts (MEFs) deficient for all three Pim kinases [triple knockout (TKO) MEFs] demonstrated activated AMPK driven by elevated ratios of AMP∶ATP relative to wild-type MEFs. Consistent with these findings, TKO MEFs were found to grow slowly in culture and have decreased rates of protein synthesis secondary to a diminished amount of 5′-cap–dependent translation. Pim-3 expression alone in TKO MEFs was sufficient to reverse AMPK activation, increase protein synthesis, and drive MEF growth similar to wild type. Pim-3 expression was found to markedly increase the protein levels of both c-Myc and the peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), enzymes capable of regulating glycolysis and mitochondrial biogenesis, which were diminished in TKO MEFs. Overexpression of PGC-1α in TKO MEFs elevated ATP levels and inhibited the activation of AMPK. These results demonstrate the Pim kinase-mediated control of energy metabolism and thus regulation of AMPK activity. We identify an important role for Pim-3 in modulating c-Myc and PGC-1α protein levels and cell growth.

1 June 2009 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ZBZanna Beharry
Zanna Beharry
MZMarina Zemskova
Marina Zemskova
SMSandeep Mahajan
Sandeep Mahajan
FZFengxue Zhang
Fengxue Zhang
JMJian Ma
Jian Ma
AKAndrew S. Kraft
Andrew S. Kraft
The Pim protein kinases play important roles in cancer development and progression, including prostate tumors and hematologic malignancies. To investigate the potential role of these enzymes as anticancer drug targets, we have synthesized novel benzylidene-thiazolidine-2,4-diones that function as potent Pim protein kinase inhibitors. With IC50 values in the nanomolar range, these compounds block the ability of Pim to phosphorylate peptides and proteins in vitro and, when added to DU145 prostate cancer cells overexpressing Pim, inhibit the ability of this enzyme to phosphorylate a known substrate, the BH3 protein BAD. When added to prostate cancer cell lines, including PC3, DU145, and CWR22Rv1, and human leukemic cells, MV4;11, K562, and U937 cells, these compounds induce G1-S cell cycle arrest and block the antiapoptotic effect of the Pim protein kinase. The cell cycle arrest induced by these compounds is associated with an inhibition of cyclin-dependent kinase 2 and activity and translocation of the Pim-1 substrate p27Kip1, a cyclin-dependent kinase 2 inhibitory protein, to the nucleus. Furthermore, when added to leukemic cells, these compounds synergize with the mammalian target of rapamycin inhibitor rapamycin to decrease the phosphorylation level of the translational repressor 4E-BP1 at sites phosphorylated by mammalian target of rapamycin. Combinations of rapamycin and the benzylidene-thiazolidine-2,4-diones synergistically block the growth of leukemic cells. Thus, these agents represent novel Pim inhibitors and point to an important role for the Pim protein kinases in cell cycle control in multiple types of cancer cells. [Mol Cancer Ther 2009;8(6):1473–83]

12 February 2007 in Oncogene
Verified
Journal Article
Closed access
JMJ Ma
J Ma
HAH K Arnold
H K Arnold
MLM B Lilly
M B Lilly
RSR C Sears
R C Sears
AKA S Kraft
A S Kraft